ENZYMOTEC LTD (ENZY) Upgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research upgraded shares of ENZYMOTEC LTD (ENZY) from UNDERPERFORM to NEUTRAL on July 15, 2014, with a target price of $15.20.

Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on ENZYMOTEC LTD (ENZY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply